{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:00:11Z","timestamp":1780059611567,"version":"3.54.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015722","name":"CHU Clermont-Ferrand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.oooo.2025.07.014","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:23:43Z","timestamp":1754436223000},"page":"e159-e166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medication-related osteonecrosis of the jaw induced by a CDK 4\/6 inhibitor (Palbociclib) in a patient who was na\u00efve to antiresorptive bone therapy: a case report"],"prefix":"10.1016","volume":"140","author":[{"given":"Elodie","family":"Pallois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Pham Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Chenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-1126","authenticated-orcid":false,"given":"Laurent","family":"Devoize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2025.07.014_bib0001","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2025.07.014_bib0002","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.oooo.2025.07.014_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.sdentj.2022.01.003","article-title":"Medication-related osteonecrosis of the jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies","volume":"34","author":"AlRowis","year":"2022","journal-title":"Saudi Dent J"},{"key":"10.1016\/j.oooo.2025.07.014_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.oooo.2025.07.014_bib0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2016.1100","article-title":"Osteonecrosis of the jaw associated with everolimus: a case report","volume":"6","author":"Yamamoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.oooo.2025.07.014_bib0006","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.oooo.2025.07.014_bib0007","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.oooo.2025.07.014_bib0008","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bulcan.2021.04.007","article-title":"[Targeting the cyclin-dependent kinases 4\/6 in advanced breast cancers]","volume":"108","author":"Coussy","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.oooo.2025.07.014_bib0009","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1016\/S1470-2045(15)00032-7","article-title":"Palbociclib for hormone receptor-positive breast cancer","volume":"16","author":"Harding","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.oooo.2025.07.014_bib0010","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2\u2212 ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2025.07.014_bib0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2025.07.014_bib0012","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1177\/10781552231165434","article-title":"Osteonecrosis of the jaw under palbociclib: a case series description","volume":"29","author":"Yosofi","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.oooo.2025.07.014_bib0013","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.3390\/ijms23052477","article-title":"Biological effects of cyclin-dependent kinase inhibitors ribociclib, palbociclib and abemaciclib on breast cancer bone microenvironment","volume":"23","author":"Iuliani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oooo.2025.07.014_bib0014","doi-asserted-by":"crossref","first-page":"9509","DOI":"10.3390\/ijerph17249509","article-title":"Medication-related osteonecrosis of the jaws and CDK4\/6 inhibitors: a recent association","volume":"17","author":"Marcian\u00f2","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.oooo.2025.07.014_bib0015","first-page":"333","article-title":"Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results. Eur Ann Otorhinolaryngol","volume":"131","author":"Robard","year":"2014","journal-title":"Head Neck Dis"},{"key":"10.1016\/j.oooo.2025.07.014_bib0016","volume":"18","author":"Fusco","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.oooo.2025.07.014_bib0017","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ijc.34962","article-title":"Association between CDK4\/6 inhibitors and drug-related osteonecrosis of the jaw: a pharmacoepidemiological study using the FDA Adverse Events Reporting System","volume":"155","author":"Go","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.oooo.2025.07.014_bib0018","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/curroncol31010016","article-title":"Relationship between medication-related osteonecrosis of the jaw and CDK4\/6 inhibitors in breast cancer","volume":"31","author":"Sen\u00edn","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.oooo.2025.07.014_bib0019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/ph13120467","article-title":"Comprehensive study of the risk factors for medication-related osteonecrosis of the jaw based on the Japanese Adverse Drug Event Report Database","volume":"13","author":"Toriumi","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.oooo.2025.07.014_bib0020","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.3390\/ijms24119284","article-title":"Palbociclib-induced cellular senescence is modulated by the mTOR complex 1 and autophagy","volume":"24","author":"Cayo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.oooo.2025.07.014_bib0021","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.18632\/oncotarget.27539","article-title":"Combined inhibition of PIM and CDK4\/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells","volume":"11","author":"Litchfield","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.oooo.2025.07.014_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.068","article-title":"Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1","volume":"31","author":"Romero-Pozuelo","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.oooo.2025.07.014_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1369420","article-title":"Confirming the efficacy and safety of CDK4\/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis","volume":"15","author":"Guan","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440325011587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440325011587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T17:06:05Z","timestamp":1762535165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440325011587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2212440325011587"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2025.07.014","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-related osteonecrosis of the jaw induced by a CDK 4\/6 inhibitor (Palbociclib) in a patient who was na\u00efve to antiresorptive bone therapy: a case report","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2025.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}